Pfizer, which has been making a name for itself for a long time with the coronavirus vaccine it developed with BioNTech, recently announced that the antiviral pill that it continues to produce against the coronavirus is 89 percent effective. The application to the US Food and Drug Administration (FDA) for the use of the drug is awaited approval.
Today, it was announced by Pfizer that the drug is also very successful in hospitalization rate according to the final test results, and also protects it from the Omicron variant.
Once approved, 180 thousand doses will be produced this year.
It was announced last month that the antiviral pill produced by Pfizer against coronavirus provides 89 percent protection in hospitalization and death rates, according to its experiments on 1200 people. Today, the final test results of the drug have been announced. According to tests involving more than 1,000 participants, no one who took Pfizer’s drug died. According to the results of a second test, there was a 70 percent decrease in the rate of hospitalization among citizens using the drug.
Mikael Dolsten, chief executive at Pfizer, commented on the data released today, “A great result. We’re talking about saving a huge number of lives and preventing hospitalization. If the drug is activated quickly after the infection, we can prevent the transmission to a great extent,” he said. He also stated that the drug worked as well in the Omicron variant as it did in other variants, according to recent laboratory tests.
Molnupavir, the coronavirus drug previously developed by the pharmaceutical company Merck, was started to be used after getting approval from the UK. Collaborating with BioNtech to produce a coronavirus vaccine, Pfizer is waiting for the result of the application to get approval for use with the antiviral pill it has developed against coronavirus. With the approval for use, the drug, which will be sold under the name Paxlovid, is planned to produce 180 thousand doses this year and at least 80 million doses next year. Paxlovid, a drug developed by Pfizer, will be released as the second coronavirus drug if approved.
17726
